Indian PE firm ChrysCapital picks 27% stake in Corona Remedies

Indian PE firm ChrysCapital picks 27% stake in Corona Remedies
Photographer: Krisztian Bocsi/Bloomberg
April 5, 2021
Indian homegrown private equity (PE) major ChrysCapital has picked up a 27% stake in Gujarat-based drug manufacturer Corona Remedies through a secondary transaction, according to a press statement issued jointly by the companies on Monday.
While other financial details of the transaction were not disclosed, DealStreetAsia had reported on March 30 that ChrysCapital is close to investing $100 million in Corona Remedies. The report also mentioned that Malaysian PE firm Creador is exiting as part of the transaction.
Creador had acquired a 20% stake in Corona Remedies for Rs 120 crore in 2016.

Related Keywords

Malaysia , Gujarat , India , Malaysian , Ankur Mehta , Kirtibhai Mehta , Nirav Mehta , Shardul Amarchand Mangaldas , Kshitij Sheth , , Corona Remedies , Capital Advisors , Vertices Partners , மலேசியா , குஜராத் , இந்தியா , மலேசியன் , அன்குர் மேத்தா , கிர்த்திபைய் மேத்தா , நீரவ் மேத்தா , ஷார்துள் அமர்சந்த் மங்கல்தாஸ் , க்ஷித்ிஜ் உறை , கொரோனா வைத்தியம் , செங்குத்துகள் கூட்டாளர்கள் ,